NANEXA - Key Persons
Job Titles:
- Co - Founder
- HEAD of INTELLECTUAL PROPERTY, CO - FOUNDER, EMPLOYED since 2009
Born: 1976
Education: MSc and PhD in Chemistry, Uppsala University.
Experience: Anders Johansson is a co-founder of Nanexa. He has previous experience of working as a patent consultant at the patent office Bjerkéns KB
Born: 1962
Education: BSc in Pharmacy, Doctor of Medical Science (DMSc) Uppsala University. EUCOR / ECPM degree in Pharmaceutical Medicine from EUCOR universities in Basel, Freiburg and Strasbourg.
Experience: Bengt Gustavsson has many years' experience from the pharmaceutical industry in Sweden and the Nordic countries, and has been Nordic Medical Director at Novartis Oncology, Nordic Clinical Research Director at Sanofi-Aventis, Nordic Medical Head of Celgene and Global Head of Medical Affairs på Oncopeptides. Bengt Gustavsson is a former reserve officer in the Swedish Air Force
Bengt Gustavsson is independent in relation to the company's major shareholders but not independent in relation to the company and its management.
Job Titles:
- Member of the Board
- BOARD MEMBER since 2021
Born: 1948
Education: BSc in Pharmacy, MSc of Pharmacy (MPharm), Uppsala University
Experience: Birgit Stattin Norinder has extensive experience from pharma and biotech companies in Sweden, the USA and the United Kingdom. She has led several Research and Development departments and has been behind a number of new and approved drugs. Birgit has been CEO and Chairman of Prolifix Ltd, Senior Vice President Worldwide Development at Pharmacia & Upjohn and Director International Regulatory Affairs at Glaxo Group Research Ltd. Birgit has also held a number of positions as a Board member and Chairman of European biotechnology companies.
Job Titles:
- CFO since 2019, EMPLOYED since 2020
Born: 1971
Education: MBA, Stockholm School of Economics
Experience: Björn Svanström has extensive experience in economics, finance and the capital market, from roles in Corporate Finance at SEB Enskilda, Group Controller at Teleca AB, CEO of Praktikertjänst's investment company Praktikerinvest and in recent years as CFO in development housing.
Born: 1960
Education: MSc in Chemistry, KTH Royal Institute of Technology Stockholm.
Experience: David Westberg has many years of experience in the pharmaceutical industry, including roles at Pharmacia, Pharmacia-UpJohn and Orexo. He has worked as a global project manager for development projects and was Head of Product Development (Pharmaceutical and Analytical Development) at Pharmacia amongst many other roles. David was also the main project manager who was responsible for taking two major Orexo products (Edluar and Zubsolv) from the early development phase through formulation development and clinical studies and onto registration and market approval with the FDA in the US.
David has also worked as a consultant on a range of business development projects in the pharmaceutical industry.
Job Titles:
- Member of the Board
- BOARD MEMBER since 2021
Born: 1964
Education: BSc in Business Administration and Executive MBA from the School of Business, Economics and Law at the University of Gothenburg
Experience: Eva Nilsagård has over 30 years' experience in senior positions, primarily in the automotive and medtech/biotech industries, such as CFO for Vitrolife, Plastal Industri and OptiGroup, Senior VP Strategy & Business development at Volvo Group Sales & Marketing EMEA, and senior positions in AstraZeneca and AB Volvo. She is Founder and CEO of Nilsagård Consulting AB, where in recent years she has held several interim positions as CEO and CFO. Professional Board career with involvement in listed, private and state-owned companies where she, among other things, contributed expertise in audit committee work and corporate governance and was involved in several IPOs. For the past ten years, Eva has acted as a mentor to several young female leaders.
Other positions: Board member of Addlife AB, Bufab AB (publ), Hansa Biopharma AB, Nimbus Group AB, Xbrane Biopharma AB and AB Svensk Exportkredit, Chairman of the Board of Spermosens AB and President and Board member of Nilsagård Consulting AB.
Holdings in Nanexa: 180 000 shares, via companies
Job Titles:
- Member of the Board
- Board Member of Novo Nordisk a / S
- Chairman of the Board of Eyepoint Pharmaceuticals
- CHAIRMAN of the BOARD since 2020
Born: 1949
Education: BSc Uppsala University, Medical degree Linköping University.
Experience: Göran Ando has over 30 years' experience in the pharmaceutical industry. He began his career in 1978 as Medical Director of Pfizer AB and continued as head of clinical research with Pfizer International in the USA. Dr. Ando then became VP, Medical and Scientific Affairs at Bristol-Myers and also returned to Sweden as President of the Astra Research Center. Between 1989 and 1995, he held a number of senior positions at Glaxo, including head of research and development for Glaxo Group Research. Dr. Ando joined Pharmacia AB in 1995 as Executive Vice President and Deputy CEO and moved to the United States in 1997 to lead research and development with additional responsibilities for manufacturing, information technology, business development and mergers and acquisitions. During his eight-year tenure as head of research and development at Pharmacia / Pharmacia & Upjohn, 17 new drugs were approved by the FDA, prior to Pfizer's acquisition of Pharmacia.
Dr. Ando was then named CEO of Celltech Group PLC in the UK, one of the most successful European biotechnology companies, until it was acquired by UCB Pharma in 2005.
Göran Ando was elected in 2005 as a board member of Novo Nordisk A / S, where he became Vice Chairman in 2006 and Chairman between 2013 and 2018.
Other positions: Göran Ando serves as Chairman of the Board of Eyepoint Pharmaceuticals (USA) and also serves as Chairman of Nouscom AG (Switzerland).
Holdings in Nanexa: 1 040 000 shares.
Göran Ando is independent in relation to the company, the company management and the company's major shareholders
Born: 1983
Education: Master of Laws, LL.M. and Bachelor´s degree Psychology, Stockholm University.
Experience: Hanna Tilus is a lawyer and partner at Cirio Advokatbyrå. Hanna has more than fifteen years of experience in the life science industry, in particular pharmaceuticals and medical technology. Her areas of expertise include commercial agreements, license arrangements, patent litigation and regulatory issues. Her previous experience includes 4.5 years as in-house counsel at Bayer where she worked mainly in the Nordic region, but also at the German headquarters.
Hanna Tilus is independent in relation to the company, the company management, and the company´s major shareholders.
Born: 1955
Education: MSc in Economics from University of Copenhagen and an MBA from INSEAD
Experience: Jakob Dynnes Hansen has 30 years of combined experience from biotech and financing. Jakob's previous experience includes CFO for more than 9 years at Evolva, a Swiss public biotech company, with a key role in the company's listing and several subsequent financings, and CFO at Danish biotech companies Nuevolution and Zealand Pharma. Before moving into biotech, Jakob was a senior member of the Corporate Finance Team at Unibank (now Nordea) and he has been Head of Market Research at Novo Nordisk.
Jakob Dynnes Hansen is independent in relation to the company, the company management and the company's major shareholders, respectively.
Job Titles:
- Head of Pharmaceutical R & D, Employed
Joel Hellrup Head of Pharmaceutical R&D, employed since 2016 Born: 1983 Education: Pharmacist degree and PhD in pharmaceutical science at Uppsala University. Experience: Joel Hellrup received his PhD in pharmaceutical science in 2016 from Uppsala University and started as a formulator at Nanexa in the same year. Joel has had a key role in the development of PharmaShell® and has several scientific articles published within the field. Other assignments: None Holdings in Nanexa: 7,000 shares, 20,000 warrants of series TO 5 (2021/2024:1), 125 000 warrants of series TO 6 (2022/2025) and 10 000 warrants of series TO 7 (2023/2026).
Job Titles:
- Senior Project Leader, Employed since 2022
Born: 1978
Education: Bachelor of Pharmaceutical Science ) at Södertörn/Uppsala
University.
Experience: Kristine Bäck has more than 20 years' experience within the pharmaceuticals industry and development projects with formulation development, preclinical and clinical studies. Kristine has long experience from roles as global project manager for clinical programmes with studies from Phase 1 to market registration and has worked at AstraZeneca, Sobi and Oncopeptides, among other companies.
Job Titles:
- HEAD of QUALITY ASSURANCE, SPECIAL ADVISOR since JUNE 2020
Born: 1962
Education: MSc Chemical Engineering, KTH Royal Institute of Technology Stockholm
Experience: Mikael Asp has more than 30 years' experience in development, Quality Assurance and manufacturing of pharmaceuticals. Mikael has worked at Pharmacia, Fresenius-Kabi, Pfizer, Oasmia and others, as Production manager, Quality manager, CTO and CEO.
Job Titles:
- Co - Founder
- HEAD of R & D ATOMIC LAYER DEPOSITION, CTO, CO - FOUNDER EMPLOYED since 2008
Born: 1977
Education: PhD in Materials Chemistry, Uppsala University.
Experience: Mårten Rooth is a co-founder of Nanexa. He has extensive experience in Atomic Layer Deposition (ALD), with several published scientific articles in the field.
Mårten Rooth is independent in relation to the company's major shareholders but not independent in relation to the company and its management.
Job Titles:
- DIRECTOR BUSINESS DEVELOPMENT since 2016
Born: 1961
Education: MSc in Engineering, KTH Royal Institute of Technology Stockholm.
Experience: Otto Skolling has worked for more than 25 years in the pharmaceutical industry, primarily in business development and financing, but also product development. Among other roles, Otto has worked at PharmaciaUpJohn (Project Director), Novozymes (Director Product Pipeline, Business Development & Director M&S Biopharmaceutical ingredients), Karolinska Development (Vice President Business Development / Portfolio Management). Otto also has extensive experience from board work in start-up companies in the pharmaceutical industry
Born: 1973
Education: Doctor of Philosophy (PhD) in Pharmacology and Bachelor of Science in Biochemical Pharmacology from University of Leicester, UK
Experience: Richard has many years of experience as an investor and executive in pharmaceutical development companies. Richard previous experience i.a. from positions as Global Oncology Venture and Transaction Lead at Johnson and Johnson, CEO of European clinical stage biotechnology company Trino Therapeutics, and Investment Manager and responsible for direct healthcare investments and venture capital funds at Wellcome Trust. Richard has been on the board of a number of biotech companies and worked closely with management teams on strategy, financing and exits via licensing, M&A and public listings.
Richard Davis is independent in relation to the Company and the company management and the Company's major shareholders, respectively.
Job Titles:
- DIRECTOR STRATEGIC MARKET ANALYSIS since 2016
Born: 1961
Education: MSc in Chemical and Administrative Sciences., University of Karlstad
Experience: Sven has broad commercial and clinical experience from the international pharmaceutical industry, based on leading positions within Pharmacia, AstraZeneca and Orexo. Sven's strength is to provide strategic commercial support in life science projects under development, preparing the projects for successful licensing or launch. In addition, Sven has several years' experience in business development and has successfully negotiated and completed several license agreements.